Performance Measures

Applicants must identify a relevant data source and demonstrate an ability to monitor program performance. The tables below provide the performance measures recipients are required to report. If more than one performance measure is provided, recipients must select at least one measure. Since this NOFO does not require recipients to conduct specific activities, measures may be altered to accommodate the program’s approach to strategy implementation and target population focus, as appropriate, with the approval of the project officer. Required performance measures must be collected and reported to CDC at least once over the period of performance.

Required Performance Measures

Required Performance Measures
Outcome Performance Measure
Increased proportion of individuals report that they are aware of their family history of cancer and report having discussed their associated cancer risk with a medical provider
  • Number of individuals who report that they have collected their family history of cancer.
  • Number of individuals who report that they have discussed their family history of cancer with a medical provider.
Improved referral patterns for cancer genetic services
  • Number of health systems and payers that have policies and practices that are concordant with recommendations for family history screening and referral of high-risk patients to genetic counseling and testing.
  • Number of health systems and clinics that have established referral networks for cancer genetic services, including tele-genetics or phone-based genetic counseling.
  • Number of health systems and clinics that have policies and practices that facilitate cascade screening.
Increased appropriate utilization of genetic counseling and genetic testing
  • Number of individuals who are referred to or use genetic counseling and/or testing when indicated.

Optional Short-Term Performance Measures

While no performance measures are required for the short-term outcomes presented in the logic model, recipients should monitor progress toward achieving these outcomes. Recipients will work with project officers to monitor progress using the suggested, but not required, performance measures and outputs below.

Optional Short-Term Performance Measures
Outcome Performance Measure
Improved data on hereditary cancer burden and utilization of cancer genetic services
  • Number of data sources used for program planning or resources (such as development of educational materials, use in surveillance, and use to address performance measures/evaluation).
Increased public awareness and knowledge about family history of cancer and benefits of genetic counseling and testing
  • Number of events, resources, or products developed, implemented, and/or disseminated to a general audience.
Increased knowledge and self-efficacy to apply professional recommendations, clinical communication, record family health history, use referral tools as recommended by USPSTF and to refer to genetic counseling and testing
  • Number of health care providers who report they are knowledgeable and confident in their ability to evaluate a patient’s family history of cancer and refer the patient to cancer genetic services when appropriate.
  • Number of specialty providers who report they are aware of universal tumor screening protocols or identifying newly diagnosed cancer patients who may benefit from cancer genetic services.
  • Number of providers who participate in educational opportunities or receive program materials.
Policy and systems change to improve access to and utilization of HBOC and LS genetic counseling, testing and risk management
  • Number of partners and stakeholders engaged in program efforts to create systems and policy change.
  • Assessment of policy, systems, and environmental factors that may improve access and use of HBOC and LS counseling, testing, and risk management.
  • Assessment of health plans to identify policies consistent with recommendations regarding referral of high-risk patients to genetic counseling, testing, and risk management.
Reduced system barriers for the access of screening and genetic services
  • Assessment of barriers and facilitators for accessing cancer genetic services.
  • Dissemination of results of assessment to relevant partners and stakeholders.

Optional Intermediate and Long-Term Performance Measures

The following intermediate and long-term outcomes in the logic model are not required. However, if applicants propose to address these outcomes, below are some suggested performance measures to consider. CDC does not require that these performance measures be reported, but if data is collected and analyzed, the findings may be reported as evaluation results and highlighted in the recipient’s annual performance report.

Optional Intermediate and Long-Term Performance Measures
Outcome Performance Measure
Increased number of providers using family history screening and tumor testing to identify individuals at high risk for hereditary cancer
  • Number of primary care providers routinely screening patient cancer family history.
  • Number of specialty providers routinely referring newly diagnosed cancer patients to germline or tumor screening.
Increased health systems with universal tumor screening protocols for LS among newly diagnosed cancer patients
  • Number of health systems with universal tumor screening protocols for LS among newly diagnosed colorectal cancers.
Increased proportion of individuals at high risk for a hereditary cancer who are counseled on and utilize risk management strategies.
  • Number of high-risk individuals who are counseled on options to manage their risk.
  • Number of high-risk individuals who receive appropriate screening.
  • Number of individuals who use chemoprevention to reduce their cancer risk.
  • Number of individuals who receive prophylactic surgeries to reduce future cancer risk.
  • Number of individuals who engage in positive behavior change.